Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The study results section now includes posted results data (ORR by RECIST v1.1 with 18-month follow-up) and related dates/documents, and Cohort 3 has been renamed from 'Safety and Tolerability' to 'Tolerability' with a 100-day dosing assessment.
    Difference
    2%
    Check dated 2026-04-05T16:47:43.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Results Submitted is now displayed and the page revision updated to v3.5.0, replacing the previous No Results Posted and revision v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-22T05:48:28.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision updated: from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-07T18:52:34.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Added Fallopian tube cancer to the listed conditions and introduced the Genetic and Rare Diseases Information Center as a resource; updated page revision from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-14T12:32:44.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.0 to v3.4.1, indicating a minor platform update. This change does not affect study content or page layout; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T07:35:08.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The changes include showing the glossary, capitalizing the QC criteria label from 'Last Update Submitted that met QC Criteria' to 'Last Update Submitted that Met QC Criteria', updating 'No FEAR Act Data' wording, and adding 'Revision: v3.4.0', while removing the older label and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-24T02:06:50.000Z thumbnail image

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.